Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Katowice – page 33

736 clinical trials in Katowice, Poland across 18 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Katowice at a glance
736
clinical trials
  • Research sites18
Type of trial
Recruitment status
Quick filters

736 trials in Katowice

Open in trial search

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of ESK-001 and Apremilast for Patients with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Alumis Inc.

Psoriatic arthropathy

Not recruiting

Study of sonelokimab and risankizumab in adults with psoriatic arthritis who did not respond well to previous TNF inhibitor treatment

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:MoonLake Immunotherapeutics AG

Psoriasis

Not recruiting

Study on the Effectiveness of LY4100511 for Adults with Moderate-to-Severe Plaque Psoriasis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ly4100511
  • Sponsor:DICE Therapeutics Inc.

Asthma

Not recruiting

Study on the Effects of Lunsekimig (SAR443765) in Adults with High-Risk Asthma Not Eligible for Biologic Treatment

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:LUNSEKIMIG
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Psoriatic arthropathy

Not recruiting

Study of sonelokimab injection in adults with active psoriatic arthritis who have not received biological DMARDs treatment before

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Psoriasis

Not recruiting

Study on Long-term Safety and Effectiveness of Zasocitinib for Patients with Moderate-to-Severe Plaque Psoriasis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Neurodermatitis

Not recruiting

Study on the Effects of Povorcitinib for Patients with Prurigo Nodularis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
  • Sponsor:Incyte Corp.

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of ESK-001 and Apremilast for Adults with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Alumis Inc.

Dermatitis atopic

Not recruiting

Study on the Safety and Effectiveness of APG777 for Patients with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Apg777
  • Sponsor:Apogee Therapeutics Inc.

Study on Dabigatran and Ticagrelor for Patients with Acute Coronary Syndrome and Atrial Fibrillation Undergoing Heart Procedure

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ticagrelor
  • Sponsor:Medical University Of Gdansk

Colitis ulcerative

Not recruiting

Study on GS-1427 for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Gs-1427
  • Sponsor:Gilead Sciences Inc.

Migraine

Not recruiting

Study on Lu AG09222 for Preventing Migraines in Adults Unresponsive to Previous Treatments

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Lu Ag09222
  • Sponsor:H. Lundbeck A/S

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Katowice

What the registry says about research in the country

01 Respiratory Conditions

Research focusing on respiratory health conditions, including studies on RSV infections in older adults and treatments for chronic obstructive pulmonary disease. Current trials are evaluating new vaccines and investigating innovative therapies for chronic rhinosinusitis.

  • RSV Vaccine Studies
  • COPD Treatment Evaluation
  • Chronic Rhinosinusitis Management
02 Neurological Disorders

Innovative research into neurodegenerative conditions, with a particular focus on Parkinson's disease treatments. Studies are examining new therapeutic approaches and investigating targeted treatments for early-stage Parkinson's.

  • Early Parkinson's Disease Interventions
  • LRRK2-Driven Parkinson's Research
  • Generalized Myasthenia Gravis Treatment
03 Dermatological Conditions

Comprehensive studies on inflammatory skin conditions, including trials for moderate to severe plaque psoriasis, genital psoriasis, and atopic dermatitis. Research focuses on evaluating new biological treatments and innovative therapies.

  • Plaque Psoriasis Treatments
  • Atopic Dermatitis Management
  • Novel Therapeutic Approaches
04 Oncology and Hematology

Advanced research in cancer treatment, particularly focusing on blood cancers and prostate cancer. Studies include innovative approaches for treating diffuse large B-cell lymphoma and acute myeloid leukemia.

  • Lymphoma Therapies
  • Leukemia Treatments
  • Prostate Cancer Management
05 Autoimmune Conditions

Research investigating treatments for various autoimmune disorders, including Sjögren's Syndrome and chronic inflammatory demyelinating polyneuropathy. Studies focus on evaluating new therapeutic agents and their long-term effectiveness.

  • Sjögren's Disease Therapies
  • CIDP Treatment Approaches
  • Inflammatory Disease Management
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.